Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 31;16(1):e53316.
doi: 10.7759/cureus.53316. eCollection 2024 Jan.

Role of Platelet-Rich Plasma in Genitourinary Syndrome of Menopause

Tejal Waghe  1 , Neema Acharya  1 , Megha Karnik  1 , Shazia Mohammad  1 , Nidhi A Patel  1 , Rinkle Gemnani  2
Affiliations
Review

Role of Platelet-Rich Plasma in Genitourinary Syndrome of Menopause

Tejal Waghe et al. Cureus. .

Abstract

The genitourinary syndrome of menopause (GSM) encompasses a range of symptoms linked to the genitourinary tract stemming from the reduction in estrogen levels following menopause. These symptoms may endure throughout a woman's lifetime. Platelet-rich plasma (PRP), known for its capacity to induce angiogenesis and the restoration effects of growth factors, has been widely employed in various disorders, including GSM. This article aims to comprehensively review the existing literature on the utilization of PRP for managing GSM. The search was executed in electronic databases, specifically PubMed, Scopus, and Google Scholar, up until April 2023. Eligible studies were meticulously chosen for inclusion in this systematic review. PRP emerges as a viable alternative for addressing vaginal atrophy, exhibiting favorable outcomes. Notably, it can be considered for patients with contraindications to hormonal therapy. However, the available body of evidence supporting the use of PRP for GSM remains limited. PRP presents itself as a promising agent, offering a patient-friendly, cost-effective alternative modality. To establish the efficacy of PRP in treating GSM definitively, future randomized trials are imperative.

Keywords: genitourinary syndrome of menopause (gsm); hyaluronic acid (ha); photodynamic therapy (pdt); platelet rich plasma (ppp); vascular endothelial growth factor (vegf).

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA methodology for literature search
Adapted from the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines
See this image and copyright information in PMC

References

    1. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Portman DJ, Gass ML. Menopause. 2014;21:1063–1068. - PubMed
    1. Genitourinary syndrome of menopause: management strategies for the clinician. Faubion SS, Sood R, Kapoor E. Mayo Clin Proc. 2017;92:1842–1849. - PubMed
    1. ACOG practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123:202–216. - PubMed
    1. Genitourinary syndrome of menopause. Farrell Am E. https://pubmed.ncbi.nlm.nih.gov/28697291/ Aust Fam Physician. 2017;46:481–484. - PubMed
    1. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Am J Obstet Gynecol. 2016;215:704–711. - PubMed

LinkOut - more resources